Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8323167 | 0.86 | PDE4A (0.46) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL27810471 | 0.84 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL18452554 | 0.84 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL28066560 | 0.78 | TSHR (0.39) | TSHR | |
| SCHEMBL9747332 | 0.78 | LMNA (0.41) | LMNATDP1TSHR | |
| SCHEMBL471726 | 0.77 | PDE4A (0.41) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1478552 | 0.77 | PDE4A (0.41) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29720316 | 0.77 | PDE4A (0.41) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL817588 | 0.77 | PDE4A (0.41) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2783948 | 0.76 | ALDH1A1 (0.37) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009129221-A1 | POLYFUNCTIONAL COMPOUNDS AND GLASS-IONOMER CEMENT COMPOSITIONS AND METHODS FOR USING AS IMPLANT MATERIALS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| JP-8119846-A | — | — | None | — | — | JP | disclosed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| CN-117204119-A | Thin film heater and glass with heater | TDK株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-117178630-A | Thin film heater and glass with heater | TDK株式会社 | 2023-12-05 | — | — | CN | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL | 2020-12-03 | — | — | US | disclosed |
| CN-107735468-B | Method for preparing organopolysiloxanes comprising (meth) acrylate functions | 蓝星有机硅法国两合公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2020-02-11 | — | — | US | disclosed |
| CN-105451746-A | Compositions comprising crosslinked cationically binding polymers | RELYPSA INC | 2016-03-30 | — | — | CN | disclosed |
| US-20150258094-A1 | Nanocarriers And Their Processing For Diagnostics And Therapeutics | RHODE ISLAND HOSPITAL | 2015-09-17 | — | — | US | disclosed |
| WO-2015139051-A2 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL (US) | 2015-09-17 | — | — | WO | disclosed |
| CN-1068182-C | Non-stick chewing gum | WARNER LAMBERT CO (US) | 2001-07-11 | — | — | CN | disclosed |
| CN-1207501-A | Lenses obtained from high-speed polymerizable resin composition | MITSUI CHEMICALS INC (JP) | 1999-02-10 | — | — | CN | disclosed |
| CN-1040651-C | High-speed polymerizable resin composition and lens made of the same | MITSUI TOATSU CHEMICALS (JP) | 1998-11-11 | — | — | CN | disclosed |
| CN-1171726-A | Non-stick chewing gum | WARNER LAMBERT CO (US) | 1998-01-28 | — | — | CN | disclosed |
| JP-H08119846-A | PROTECTING AGENT FOR SKIN | SUZUKI YUSHI KOGYO KK | 1996-05-14 | — | — | JP | disclosed |
| CN-1106841-A | High-speed polymerizable resin composition and lens made of the same | MITSUI TOATSU CHEMICALS (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0097864-A1 | Photopolymerizable mixture and photopolymerizable copying material produced therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258094-A1 | Nanocarriers And Their Processing For Diagnostics And Therapeutics | SYVN1, SSB, TNF | PDE4A 2797/4885LMNA 379/4885L3MBTL1 2881/4885 |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | PDE4A 2671/4885LMNA 415/4885L3MBTL1 693/4885 |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | PDE4A 2671/4885LMNA 415/4885L3MBTL1 693/4885 |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | PDE4A 2797/4885LMNA 379/4885L3MBTL1 2881/4885 |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | SYVN1, SSB, TNF | PDE4A 2797/4885LMNA 379/4885L3MBTL1 2881/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | PDE4A 2671/4885LMNA 415/4885L3MBTL1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.